Spots Global Cancer Trial Database for Study of INBRX-109 in Conventional Chondrosarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of INBRX-109 in Conventional Chondrosarcoma
Official Title: A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Study ID: NCT04950075
Conditions
Study Description
Brief Summary: Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Detailed Description: This is a randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. INBRX-109 is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic Cancer Center, Phoenix, Arizona, United States
University of California, San Francisco (UCSF), San Francisco, California, United States
Sarcoma Oncology Center, Santa Monica, California, United States
University of Colorado, Denver, Colorado, United States
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Northwestern University - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
Rush Cancer Center, Chicago, Illinois, United States
University of Iowa, Iowa City, Iowa, United States
Johns Hopkins, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
Washington University School of Medicine - St. Louis, Saint Louis, Missouri, United States
Nebraska Methodist Hospital, Omaha, Nebraska, United States
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Columbia University, New York, New York, United States
Duke University, Durham, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
Oklahoma State University (OSU) - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Oregon Health & Science University (OHSU) Knight Cancer Institute, Portland, Oregon, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
University of Texas Southwestern, Dallas, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Washington University - Seattle, Seattle, Washington, United States
Royal Adelaide Hospital, Adelaide, , Australia
Chris O'Brien Lifehouse, Camperdown, , Australia
Princess Alexandra Hospital, Woolloongabba, , Australia
Institut Bergonie, Bordeaux, Cedex, France
Centre Leon Berard, Lyon, , France
AP-HM - Hôpital de la Timone, Marseille, , France
Gustave Roussy, Villejuif, , France
Helios Klinikum Berlin-Buch, Berlin, , Germany
Universitätsmedizin Mannheim, Mannheim, , Germany
Saint Vincent's University Hospital part of Irish Sarcoma Group, Dublin, , Ireland
IRCCS Istituto Ortopedico Rizzoli di Bologna, Bologna, , Italy
La Fondazione e l'Istituto di Candiolo, Candiolo, , Italy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, , Italy
Nuovo Ospedale di Prato, Prato, , Italy
Policlinico Universitario Campus Biomedico, Roma, , Italy
Groningen UMC, Groningen, , Netherlands
Leiden University Medical Center, Leiden, , Netherlands
Hospital Universitario Vall d'Hebron, Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau Barcelona, Barcelona, , Spain
Hospital Clinico San Carlos, Madrid, , Spain
Hospital Fundación Jiménez Díaz, Madrid, , Spain
Hospital Universitari i Politecnic La Fe, Valencia, , Spain
University College London Hospital (UCL), London, , United Kingdom
Royal Marsden NHS Foundation Trust, London, , United Kingdom
The Christie NHS Foundation Trust, Manchester, , United Kingdom
Churchill Hospital, Oxford, , United Kingdom
Contact Details
Name: Clinical Lead
Affiliation: Inhibrx Biosciences, Inc
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
